AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9476268 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint space width measurement
Number of subjects: 463
Study 9476268 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic progression
Number of subjects: 463
Study 8177098 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (20 micrograms ethinyl estradiol and 150 micrograms desogestrel) for 6 months
Number of subjects: 59
Study 8177098 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 59
Study 3653128 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen therapy (polyestradiol phosphate 80 mg i.m. per month + 150 micrograms ethinylestradiol p.o. per day)
Number of subjects: 100
Study 3653128 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen therapy
Number of subjects: 100
Study 3653128 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 100
Study 28301911 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) treatment
Number of subjects: 400
Study 28301911 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet function analysis using ASPItest and TRAPtest
Number of subjects: 400
Study 27940956 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg subcutaneously before intervention, followed by 0.6 mg for 2 days, 1.2 mg for 2 days, and 1.8 mg for 3 days)
Number of subjects: 96
Study 27940956 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 96
Study 27940956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 26575873 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline 1 mg/kg, once every 8 hours
Number of subjects: 40
Study 26575873 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 2 mg/kg, once every 8 hours
Number of subjects: 40
Study 23725303 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1%
Number of subjects: 171
Study 23725303 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.3%
Number of subjects: 171
Study 23725303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05%
Number of subjects: 171
Study 23725303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 21504340 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of oral micronized progesterone capsules (Utrogestan 3 x 100 mg) and vaginal progesterone gel (Crinone 8%, 90 mg daily)
Number of subjects: 370
Study 21504340 — intervention group
Group type: COMPARATOR
Intervention: Progesterone monotherapy (vaginal progesterone gel, Crinone 8%, 90 mg daily)
Number of subjects: 370
Study 21504340 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 370
Study 21504340 — intervention group
Group type: COMPARATOR
Intervention: Progesterone monotherapy
Number of subjects: 370
Study 18425621 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (THL) in combination with riluzole
Number of subjects: 37
Study 18425621 — intervention group
Group type: COMPARATOR
Intervention: Riluzole alone
Number of subjects: 37
Study 16495259 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate suppositories (8 to 16 mg/kg at 0 and 12 h, then daily)
Number of subjects: 79
Study 16495259 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular artemether (3.2 mg/kg at 0 h, then 1.6 mg/kg daily)
Number of subjects: 79
Study 14511846 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 5 mg
Number of subjects: 0
Study 14511846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 0
Study 14511846 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 2 mg
Number of subjects: 0
Study 11045860 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 103)
Number of subjects: 205
Study 11045860 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 102)
Number of subjects: 205
Study 8733987 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aerosol nasal inhaler (220 micrograms/d)
Number of subjects: 116
Study 8733987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 2317442 — intervention group
Group type: EXPERIMENTAL
Intervention: Inderal LA 80 mg
Number of subjects: 12
Study 2317442 — intervention group
Group type: EXPERIMENTAL
Intervention: Inderal LA 160 mg
Number of subjects: 12
Study 2317442 — intervention group
Group type: EXPERIMENTAL
Intervention: Inderal LA 320 mg
Number of subjects: 12
Study 7000166 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 0
Study 7000166 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 0
Study 31137994 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with LP Nd:YAG laser and 10% KOH application
Number of subjects: 38
Study 31137994 — intervention group
Group type: COMPARATOR
Intervention: LP Nd:YAG laser therapy only
Number of subjects: 38
Study 31124397 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance/movement training (DMT; n=12)
Number of subjects: 40
Study 31124397 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AT; n=14)
Number of subjects: 40
Study 31124397 — intervention group
Group type: COMPARATOR
Intervention: Wait list (WL; n=14)
Number of subjects: 40
Study 28081824 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 4385
Study 28081824 — intervention group
Group type: COMPARATOR
Intervention: OxPL-apoB
Number of subjects: 4385
Study 25869983 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified osteotomy design (angled oblique buccal bone cut)
Number of subjects: 28
Study 25869983 — intervention group
Group type: COMPARATOR
Intervention: Conventional osteotomy design
Number of subjects: 28
Study 22434336 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to the same initial piece during follow-up sessions
Number of subjects: 36
Study 22434336 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to the same initial piece during follow-up sessions (distraction condition)
Number of subjects: 36
Study 22434336 — intervention group
Group type: COMPARATOR
Intervention: Listening to nonmusical sounds after learning the piece
Number of subjects: 36
Study 22152087 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 7) that participated in supine resistance and aerobic exercise training
Number of subjects: 15
Study 22152087 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8) that remained physically inactive
Number of subjects: 15
Study 22152087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (exercise and control)
Number of subjects: 15
Study 20384011 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious condition (high-threat)
Number of subjects: 14
Study 20384011 — intervention group
Group type: COMPARATOR
Intervention: Calm condition (low-threat)
Number of subjects: 14
Study 16519641 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard postoperative care plus immediate use of chewing gum
Number of subjects: 38
Study 16519641 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care (control group)
Number of subjects: 38
Study 14521655 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal RV Coil Position
Number of subjects: 31
Study 14521655 — intervention group
Group type: COMPARATOR
Intervention: Proximal RV Coil Position
Number of subjects: 31
Study 10648268 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin cocktail containing 272 mg vitamin C, 31 mg all‐rac‐alpha‐tocopheryl acetate, and 400 microg folic acid
Number of subjects: 75
Study 10648268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 9144686 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 intravenously over 3 hours for eight cycles (6 months)
Number of subjects: 208
Study 9144686 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with oral cyclophosphamide (100 mg/m2/d days 1 through 14), intravenous methotrexate (40 mg/m2 days 1 and 8), intravenous 5-fluorouracil (600 mg/m2 days 1 and 8), and oral prednisolone (40 mg/m2/d days 1 through 14) for six cycles (6 months)
Number of subjects: 208
Study 8129554 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroquinidine (600 mg per 24 hours)
Number of subjects: 14
Study 8129554 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (1100 mg)
Number of subjects: 14
Study 3315608 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 86
Study 3315608 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 86
Study 29023825 — intervention group
Group type: EXPERIMENTAL
Intervention: GenIce tool for generating hydrogen-disordered ice structures
Number of subjects: 0
Study 29023825 — intervention group
Group type: EXPERIMENTAL
Intervention: GenIce tool
Number of subjects: 0
Study 29023825 — intervention group
Group type: EXPERIMENTAL
Intervention: GenIce algorithm
Number of subjects: 0
Study 27764842 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT)
Number of subjects: 83
Study 24702733 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with metformin
Number of subjects: 699
Study 24702733 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin with rosiglitazone
Number of subjects: 699
Study 24702733 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin with intensive lifestyle intervention
Number of subjects: 699
Study 24702733 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 699
Study 24702733 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 699
Study 23030572 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher text cohesion
Number of subjects: 42
Study 23030572 — intervention group
Group type: COMPARATOR
Intervention: Lower text cohesion
Number of subjects: 42
Study 20446889 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intake (average daily intake 144.8 IU, SD 84.6)
Number of subjects: 207
Study 20446889 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake (average daily intake 966.4 mg, SD 273.7)
Number of subjects: 207
Study 20446889 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D supplementation
Number of subjects: 207
Study 20446889 — intervention group
Group type: COMPARATOR
Intervention: Osteoporosis medications
Number of subjects: 207
Study 18611063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lanthanum chloride
Number of subjects: 0
Study 18611063 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lanthanum carbonate (3000 mg/day)
Number of subjects: 0
Study 18611063 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lanthanum carbonate
Number of subjects: 0
Study 16182831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 205
Study 16182831 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine-ME
Number of subjects: 205
Study 16182831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and Cyclosporine-ME
Number of subjects: 205
Study 12851624 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP579 (60 mcg/kg)
Number of subjects: 311
Study 12851624 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP579 (other doses)
Number of subjects: 311
Study 12851624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 12851624 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP579 (all doses)
Number of subjects: 311
Study 11601221 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (ALG) combined with cyclosporine A (CsA) - Intensive immunosuppressive therapy (IIST)
Number of subjects: 0
Study 11601221 — intervention group
Group type: COMPARATOR
Intervention: Antilymphocyte globulin (ALG) alone - Non-intensive immunosuppressive therapy (NIIST)
Number of subjects: 0
Study 8678273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled mechanical ventilation with PEEP and permissive hypercapnia, body position changes, inhalation of nitric oxide.
Number of subjects: 0
Study 8678273 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO) as an additional therapeutic option if other procedures fail.
Number of subjects: 0
Study 8678273 — intervention group
Group type: COMPARATOR
Intervention: Traditional standard treatment (not specified in detail).
Number of subjects: 0
Study 1411294 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily)
Number of subjects: 40
Study 1411294 — intervention group
Group type: COMPARATOR
Intervention: Bismuth compound (120 mg four times daily)
Number of subjects: 40
Study 1411294 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 3847874 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally self-blaming rape victims (present self-blame)
Number of subjects: 144
Study 3847874 — intervention group
Group type: COMPARATOR
Intervention: Non-behaviorally self-blaming rape victims (absent self-blame)
Number of subjects: 144
Study 29724622 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin 910 6‐0 suture (Vicryl, Ethicon, Johnson and Johnson Ltd., India)
Number of subjects: 60
Study 29724622 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanone 6‐0 suture (PDS II, Ethicon, Johnson and Johnson Ltd., India)
Number of subjects: 60
Study 27550310 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cm coverage size
Number of subjects: 63
Study 27550310 — intervention group
Group type: COMPARATOR
Intervention: 8 cm coverage size
Number of subjects: 63
Study 24680768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus administered via site-specific radiolabeled delivery capsule (1 mg in 2 mg/mL solution)
Number of subjects: 6
Study 24680768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus administered via site-specific radiolabeled delivery capsule
Number of subjects: 6
Study 22739083 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling by registered dietitians during ordinary diet and delivered meal period
Number of subjects: 200
Study 22739083 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-controlled meals during ordinary diet and delivered meal period
Number of subjects: 200
Study 22739083 — intervention group
Group type: COMPARATOR
Intervention: Ordinary diet without dietary counseling
Number of subjects: 200
Study 22739083 — intervention group
Group type: COMPARATOR
Intervention: Calorie-controlled meals without dietary counseling
Number of subjects: 200
Study 20199989 — intervention group
Group type: EXPERIMENTAL
Intervention: Family nutritional support
Number of subjects: 180
Study 20199989 — intervention group
Group type: COMPARATOR
Intervention: Control (antiretroviral treatment only)
Number of subjects: 180
Study 18279690 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermicides containing nonoxynol-9 (N-9)
Number of subjects: 640
Study 18279690 — intervention group
Group type: EXPERIMENTAL
Intervention: Three gels containing different doses of N-9
Number of subjects: 640
Study 18279690 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different formulations containing the same dose of N-9
Number of subjects: 640
Study 18279690 — intervention group
Group type: EXPERIMENTAL
Intervention: Different formulations and doses of spermicides containing N-9
Number of subjects: 640
Study 16167911 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of levobupivacaine
Number of subjects: 437
Study 16167911 — intervention group
Group type: COMPARATOR
Intervention: 25 mg of racemic bupivacaine
Number of subjects: 437
Study 12759801 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan augmented (T+)
Number of subjects: 96
Study 12759801 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan depleted (T-)
Number of subjects: 96
Study 12759801 — intervention group
Group type: EXPERIMENTAL
Intervention: T+
Number of subjects: 96
Study 12759801 — intervention group
Group type: COMPARATOR
Intervention: T-
Number of subjects: 96
Study 12759801 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma tryptophan
Number of subjects: 96
Study 10327295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (SCT) 200 IU
Number of subjects: 0
Study 10327295 — intervention group
Group type: COMPARATOR
Intervention: Nasal salmon calcitonin (SCT)
Number of subjects: 0
Study 8904258 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg lidocaine (LD)
Number of subjects: 30
Study 8904258 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg meperidine (MP)
Number of subjects: 30
Study 8904258 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mu g fentanyl (FN)
Number of subjects: 30
Study 2003893 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative diflunisal
Number of subjects: 24
Study 2003893 — intervention group
Group type: COMPARATOR
Intervention: Postoperative placebo
Number of subjects: 24
Study 6280796 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychemotherapy with cyclophosphamid + 5‐FU + MTX + vinblastin
Number of subjects: 859
Study 6280796 — intervention group
Group type: COMPARATOR
Intervention: New designed intermittent polychemotherapy-schedule (alternating cyclophosphamid + CCNU + MTX, then cyclophosphamid + adriamycin + vincristin, then ifosfamid + VP‐16) followed by radiation therapy
Number of subjects: 859
Study 30721171 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 21
Study 30721171 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 21
Study 30721171 — intervention group
Group type: COMPARATOR
Intervention: Both LASIK and SMILE
Number of subjects: 21
Study 30103334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed Adaptive CCT
Number of subjects: 82
Study 30103334 — intervention group
Group type: COMPARATOR
Intervention: Non-Adaptive CCT (active control)
Number of subjects: 82
Study 27821398 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational product (IP) management through coordination of IP-related operations
Number of subjects: 0
Study 27821398 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination of IP supply activities
Number of subjects: 0
Study 27821398 — intervention group
Group type: EXPERIMENTAL
Intervention: Education to site pharmacists
Number of subjects: 0
Study 27821398 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance monitoring
Number of subjects: 0
Study 24174321 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational Atherectomy (RA) with Impella 2.5
Number of subjects: 448
Study 24174321 — intervention group
Group type: COMPARATOR
Intervention: Rotational Atherectomy (RA) with IABP
Number of subjects: 448
Study 24174321 — intervention group
Group type: COMPARATOR
Intervention: No Rotational Atherectomy (RA) with Impella
Number of subjects: 448
Study 24174321 — intervention group
Group type: COMPARATOR
Intervention: No Rotational Atherectomy (RA) with IABP
Number of subjects: 448
Study 23206459 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prolonged-release oxycodone/naloxone (OXN PR)
Number of subjects: 0
Study 20937657 — intervention group
Group type: EXPERIMENTAL
Intervention: LP/HGI
Number of subjects: 827
Study 20937657 — intervention group
Group type: EXPERIMENTAL
Intervention: HP/LGI
Number of subjects: 827
Study 20937657 — intervention group
Group type: EXPERIMENTAL
Intervention: LP/LGI
Number of subjects: 827
Study 20937657 — intervention group
Group type: EXPERIMENTAL
Intervention: HP/HGI
Number of subjects: 827
Study 20937657 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 827
Study 18780534 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization appliance (S group)
Number of subjects: 65
Study 18780534 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated occlusal appliance (R group)
Number of subjects: 65
Study 18780534 — intervention group
Group type: COMPARATOR
Intervention: Both groups (S and R)
Number of subjects: 65
Study 16203271 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine/docetaxel combination therapy
Number of subjects: 511
Study 16203271 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel monotherapy
Number of subjects: 511
Study 11857049 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed supplementation (1.3 g/100 g ground flaxseed and 5 g/100 g flaxseed oil)
Number of subjects: 80
Study 11857049 — intervention group
Group type: COMPARATOR
Intervention: Control diet (non-supplemented foods)
Number of subjects: 80
Study 10439881 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose glucose-insulin-potassium (GIK)
Number of subjects: 954
Study 8590846 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG-CSF (5 micrograms/kg/day for 5 days)
Number of subjects: 14
Study 8590846 — intervention group
Group type: COMPARATOR
Intervention: CHOP alone (control group)
Number of subjects: 14
Study 2501313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 8
Study 2501313 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate as Isotard Forte
Number of subjects: 8
Study 2501313 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate as Cordil-40 SR
Number of subjects: 8
Study 2501313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29802320 — intervention group
Group type: EXPERIMENTAL
Intervention: Massively parallel sequencing (MPS) genetic testing
Number of subjects: 122
Study 29802320 — intervention group
Group type: COMPARATOR
Intervention: Usual care genetic testing
Number of subjects: 122
Study 28219959 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet transplantation
Number of subjects: 30
Study 28219959 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 30
Study 25199856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary NO3(‐) intake (140 mL of concentrated beetroot juice containing 11.2 mmol of NO3(‐))
Number of subjects: 12
Study 25199856 — intervention group
Group type: COMPARATOR
Intervention: Placebo (140 mL of beetroot juice devoid of NO3(‐))
Number of subjects: 12
Study 23726325 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating-rotating electric toothbrush with a specially designed orthodontic brush head (Oral-B Triumph, OD17)
Number of subjects: 46
Study 23726325 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating-rotating electric toothbrush with a regular brush head (EB25)
Number of subjects: 46
Study 23726325 — intervention group
Group type: COMPARATOR
Intervention: Regular manual toothbrush (American Dental Association)
Number of subjects: 46